Cargando…
Tsunami of immunotherapy reaches mesothelioma
Malignant pleural mesothelioma (MPM) is the most common type of malignant mesothelioma. It is a rare tumor linked to asbestos exposure and is associated with a poor prognosis. Until very recently, patients with advanced or unresectable disease had limited treatment options, primarily based on double...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052072/ https://www.ncbi.nlm.nih.gov/pubmed/35582652 http://dx.doi.org/10.5306/wjco.v13.i4.267 |
_version_ | 1784696707005546496 |
---|---|
author | Mielgo-Rubio, Xabier Cardeña Gutiérrez, Ana Sotelo Peña, Verónica Sánchez Becerra, Maria Virginia González López, Andrea María Rosero, Adriana Trujillo-Reyes, Juan Carlos Couñago, Felipe |
author_facet | Mielgo-Rubio, Xabier Cardeña Gutiérrez, Ana Sotelo Peña, Verónica Sánchez Becerra, Maria Virginia González López, Andrea María Rosero, Adriana Trujillo-Reyes, Juan Carlos Couñago, Felipe |
author_sort | Mielgo-Rubio, Xabier |
collection | PubMed |
description | Malignant pleural mesothelioma (MPM) is the most common type of malignant mesothelioma. It is a rare tumor linked to asbestos exposure and is associated with a poor prognosis. Until very recently, patients with advanced or unresectable disease had limited treatment options, primarily based on doublet chemotherapy with cisplatin and pemetrexed. In 2020 and 2021, after more than a decade with no major advances or new drugs, two phase III clinical trials published results positioning immunotherapy as a promising option for the first- and second-line treatment of MPM. Immunotherapy has revolutionized the treatment of many cancers and is also showing encouraging results in malignant mesothelioma. Both immune checkpoint inhibition and dual cytotoxic T-lymphocyte–associated antigen 4 and programmed death-ligand 1 pathway blockade resulted in significantly improved overall survival in randomized phase III trials. In the CheckMate 743 trial, first-line therapy with nivolumab plus ipilimumab outperformed standard chemotherapy, while in the CONFIRM trial, nivolumab outperformed placebo in patients previously treated with chemotherapy. These two trials represent a major milestone in the treatment of MPM and are set to position immunotherapy as a viable alternative for treatment-naïve patients and patients with progressive disease after chemotherapy. |
format | Online Article Text |
id | pubmed-9052072 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-90520722022-05-16 Tsunami of immunotherapy reaches mesothelioma Mielgo-Rubio, Xabier Cardeña Gutiérrez, Ana Sotelo Peña, Verónica Sánchez Becerra, Maria Virginia González López, Andrea María Rosero, Adriana Trujillo-Reyes, Juan Carlos Couñago, Felipe World J Clin Oncol Minireviews Malignant pleural mesothelioma (MPM) is the most common type of malignant mesothelioma. It is a rare tumor linked to asbestos exposure and is associated with a poor prognosis. Until very recently, patients with advanced or unresectable disease had limited treatment options, primarily based on doublet chemotherapy with cisplatin and pemetrexed. In 2020 and 2021, after more than a decade with no major advances or new drugs, two phase III clinical trials published results positioning immunotherapy as a promising option for the first- and second-line treatment of MPM. Immunotherapy has revolutionized the treatment of many cancers and is also showing encouraging results in malignant mesothelioma. Both immune checkpoint inhibition and dual cytotoxic T-lymphocyte–associated antigen 4 and programmed death-ligand 1 pathway blockade resulted in significantly improved overall survival in randomized phase III trials. In the CheckMate 743 trial, first-line therapy with nivolumab plus ipilimumab outperformed standard chemotherapy, while in the CONFIRM trial, nivolumab outperformed placebo in patients previously treated with chemotherapy. These two trials represent a major milestone in the treatment of MPM and are set to position immunotherapy as a viable alternative for treatment-naïve patients and patients with progressive disease after chemotherapy. Baishideng Publishing Group Inc 2022-04-24 2022-04-24 /pmc/articles/PMC9052072/ /pubmed/35582652 http://dx.doi.org/10.5306/wjco.v13.i4.267 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
spellingShingle | Minireviews Mielgo-Rubio, Xabier Cardeña Gutiérrez, Ana Sotelo Peña, Verónica Sánchez Becerra, Maria Virginia González López, Andrea María Rosero, Adriana Trujillo-Reyes, Juan Carlos Couñago, Felipe Tsunami of immunotherapy reaches mesothelioma |
title | Tsunami of immunotherapy reaches mesothelioma |
title_full | Tsunami of immunotherapy reaches mesothelioma |
title_fullStr | Tsunami of immunotherapy reaches mesothelioma |
title_full_unstemmed | Tsunami of immunotherapy reaches mesothelioma |
title_short | Tsunami of immunotherapy reaches mesothelioma |
title_sort | tsunami of immunotherapy reaches mesothelioma |
topic | Minireviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052072/ https://www.ncbi.nlm.nih.gov/pubmed/35582652 http://dx.doi.org/10.5306/wjco.v13.i4.267 |
work_keys_str_mv | AT mielgorubioxabier tsunamiofimmunotherapyreachesmesothelioma AT cardenagutierrezana tsunamiofimmunotherapyreachesmesothelioma AT sotelopenaveronica tsunamiofimmunotherapyreachesmesothelioma AT sanchezbecerramariavirginia tsunamiofimmunotherapyreachesmesothelioma AT gonzalezlopezandreamaria tsunamiofimmunotherapyreachesmesothelioma AT roseroadriana tsunamiofimmunotherapyreachesmesothelioma AT trujilloreyesjuancarlos tsunamiofimmunotherapyreachesmesothelioma AT counagofelipe tsunamiofimmunotherapyreachesmesothelioma |